ONM-501, a dual-activating polyvalent STING agonist, enhances tumor retention and demonstrates favorable preclinical safety profile
Previous
Previous
Improved Tolerability and Tumor Specific Delivery of a Therapeutic Bispecific T Cell Engager Using a pH-Sensitive Nanoparticle Platform
Next
Next